Zomedica Reports Record Second Quarter Revenue and Reduced Net Loss

Zomedica Corp., an animal health company, achieved record revenue of $9.5 million in the second quarter of 2026, marking a 37% increase year-over-year. The company's net loss was reduced by 49%, showing significant financial improvement. The growth was largely driven by strong performance in therapeutic devices, increased adoption of diagnostic offerings like the TRUFORMA® platform, and contributions from the Development Services segment.

Revenue from Diagnostics surged by 77%, while Therapeutic Devices saw a 9% rise. The Development Services segment added revenue of $1.4 million. The company also noted a 16% increase in core commercial business revenue, excluding Development Services.

Operating expenses fell by 20%, reflecting disciplined cost management. Notably, Zomedica’s cash burn decreased by 38%, netting a record low of $3.4 million. Gross margin stood at 64% for the quarter. Zomedica maintains a strong balance sheet with $44.1 million in liquidity as of June 30, 2026.